Roundtable Discussion: Enhancing the Scalability of Digital Biomarkers for Neurological Indications
Time: 11:30 am
day: Day Two
Details:
- Exploring how digital biomarkers relate to clinical outcomes that payers, HTAs, and other reimbrusement bodies accept, value, and demand
- Discussing challenges and opportunities in deploying digital biomarkers at scale outside a clinical trial setting, addressing issues related to desireability, data privacy, regulatory compliance, and technological infrastructure
- Examining case studies and best practices for implementing scalable digital biomarker solutions in clinical trials and real-world clinical settings to advance CNS research and patient care
- Evaluating real world evidence as the role for health outcome studies in the post-launch phase
